MPM is a treatment-resistant disease pathogenically related to chronic inflammation. Research recently published in the British Journal of Cancer concludes that fibrinogen measured in the plasma of patients with MPM prior to treatment provides clinical utility as an independent biomarker capable of predicting treatment outcomes. While more investigation is needed, the identification of a prognostic biomarker is a promising advancement for the future of care in this devastating disease.